
References

- Al Badr W, Martin KJ. 2009 : Role of bone biopsy in renal osteodystrophy. Saudi J Kidney Dis Transpl 20:12-9.
- Alon U, Davidai G, Bentur L. 1986: Oral calcium carbonate as phosphate-binder in infants and children with chronic renal failure. Miner Electrolyte Metab. 12:320-325
- Amann K, Tornig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, Szabo A, Ritz E. 2003: Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int ; 63:1296–1301.
- Amaral S, Hwang W, Fivush B, Neu A, Frankenfield D, Furth S. 2006: Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol 17: 2878–2885.
- Andress DL, Endres DB, Maloney NA. 1986: Comparison of parathyroid hormone assays with bone histomorphometry in renal osteodystrophy. J Clin Endocrinol Metab. 63: 1163-1169.
- Antonsen JE, Sherrard DJ, Andress DL. 1998: A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Tnt .53:223-227.
- Armas, L.A., Hollis, B.W. & Heaney, R.P. 2004: “Vitamin D2 is much less effective than vitamin D3 in humans”, The Journal of clinical endocrinology and metabolism, vol. 89, no. 11, pp. 5387-5391.
- Arnold A, Brown MF, Urena P. 1995: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest. 95:2047-2053.
- Arora P and Verrelli M. 2008: Chronic Renal Failure. <http://www.emedicine.com>.
- Avesani CM, Carrero JJ, Axelsson J, Qureshi AR, Lindholm B, Stenvinkel P. 2006: Inflammation and wasting in chronic kidney disease: partners in crime. Kidney Int Suppl ;1:S8-S13.
- Avila-Díaz M, Matos M, García-López E, Prado MD, Castro-Vázquez F, Ventura MD, González E, Amato D, Paniagua R. 2006: Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis. Perit Dial Int. Jan-Feb;26(1):78-84.
- Axelsson J, Bergsten A, Qureshi AR, et al., 2006. Elevated resistin levels in chronic kidney disease are associated with

decreased glomerular filtration rate and inflammation, but not with insulin resistance. *Kidney Int.* 69:596-604.

- Bailey, D.A., McKay, H.A., Mirwald, R.L., Crocker, P.R. & Faulkner, R.A. 1999: "A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study", *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, vol. 14, pp. 1672-1679.
- Baker LR, Abrams L, Roe CJ. 1989: 1,25(OH)2D3 and administration in moderate renal failure: a prospective double-blind trial. *Kidney int.* 35:661-669.
- Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, Salusky IB. 2010: Value of the new bone classification system in pediatric renal osteodystrophy. *Clin J Am Soc Nephrol.* Oct;5(10):1860-6.
- Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y. 2006: Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. *Kidney Int.* 69:1081-1087.
- Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. 2003: Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. *Kidney Int.* 64:2238-2243.
- Baroncelli, G.I., Bertelloni, S., Ceccarelli, C., Cupelli, D. & Saggese, G. 2000: "Dynamics of bone turnover in children with GH deficiency treated with GH until final height", *European journal of endocrinology / European Federation of Endocrine Societies*, vol. 142, no. 6, pp. 549-556.
- Bass, S., Delmas, P.D., Pearce, G., Hendrich, E., Tabensky, A. & Seeman, E. 1999: "The differing tempo of growth in bone size, mass, and density in girls is regionspecific", *The Journal of clinical investigation*, vol. 104, no. 6, pp. 795-804.
- Baxter-Jones, A.D., Kontulainen, S.A., Faulkner, R.A. & Bailey, D.A. 2008: "A longitudinal study of the relationship of physical activity to bone mineral accrual from adolescence to young adulthood", *Bone*, vol. 43, no. 6, pp. 1101-1107.
- Behnke B, Kemper M, Kruse HP, Muller Wiefel DE. 1998: Bone alkaline phosphatase in children with chronic renal failure. *Nephrol Dial Transplant.* 13(3):662-7.

-
- Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. 2001: The effect of a single dose of Osteoprotegerin in postmenopausal women. *J Bone Miner Res.* 16:348- 360.
 - Berger N, Mehis O, Schmitt CP. 1996: Daily calcitriol but not pulse therapy improves growth in experimental uremia (Abstract). *J Am Soc Nephrol.* 7:1789.
 - Bishop, N. 1999: “Rickets today--children still need milk and sunshine”, *The New England journal of medicine*, vol. 341, no. 8, pp. 602-604.
 - Blake C, O'Meara YM. 2004: Subjective and objective physical limitations in high-functioning renal dialysis patients. *Nephrol Dial Transplant.* 19:3124-3129.
 - Blum WF, Ranke MB, Kietzmann K. 1997: Growth hormone resistance and inhibition of somatomedin activity by excess of insulin growth factor binding protein in uremia. *Pediatr Nephrol.* 11:539-544.
 - Boccardo P, Remuzzi G, Galbusera M. 2004: Platelet dysfunction in renal failure. *Semin Thromb Hemost.* 30:579-589.
 - Boot, A.M., Engels, M.A., Boerma, G.J., Krenning, E.P. & De Muinck Keizer- Schrama, S.M. 1997: “Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency”, *The Journal of clinical endocrinology and metabolism*, vol. 82, no. 8, pp. 2423-2428.
 - Boyce, B.F. & Xing, L. 2008: “Functions of RANKL/RANK/OPG in bone modeling and remodeling”, *Archives of Biochemistry and Biophysics*, vol. 473, no. 2, pp. 139-146.
 - Braun J, Oldendorf M, Moshage W 1996: Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients. *Am J Kidney Dis.* 27:394-401.
 - Brown EM. 1981: Set point for calcium: its role in normal and abnormal secretion. In: Cohn DV, Talmage RV, Matthews JL, eds. *Hormonal Control of calcium Metabolism*. Amsterdam: Excerpta Medica. 35.
 - Brown EM. 1983: Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. *J Clin Endocrinol Metab.* 56:572-581.
-

-
- Brown EM, Hebert SC. 1997: Calcium-receptor-regulated parathyroid and renal function. *Bone*. 20:303-309.
 - Brown AJ, Ritter CS, Finch JL, Slatopolsky EA. 1999: Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: Role of dietary phosphate. *Kidney Int* 1284–1292.
 - Brown E.M. & Juppner H. 2006: "Parathyroid hormone: Synthesis, secretion, and action", in *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, Sixth edn, Washington, D.C., the American Society for Bone and Mineral Research, pp. 90-99.
 - Bucay, N., Sarosi, I., Dunstan, C.R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H.L., Xu, W., Lacey, D.L., Boyle, W.J. & Simonet, W.S. 1998: "Osteoprotegerin- Deficient Mice Develop Early Onset Osteoporosis and Arterial Calcification", *Genes & development*, vol. 12, no. 9, pp. 1260-1268 .
 - Burke JR. 1995: Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure. Australian and New Zealand Paediatric Nephrology Association. *Pediatr Nephrol* 9: 558–561.
 - Cameron, M.A., Paton, L.M., Nowson, C.A., Margerison, C., Frame, M. & Wark, J.D. 2004: "The effect of calcium supplementation on bone density in premenarcheal females: a co-twin approach", *The Journal of clinical endocrinology and metabolism*, vol. 89, no. 10, pp. 4916-4922.
 - Canaud B, Morena M, Leray-Moragues H, Chalabi L, Cristol JP. 2006: Overview of clinical studies in hemodiafiltration: what do we need now? *Hemodial Int*. 10:Suppl 1:S5-S12.
 - Cannata JB, Briggs JD, Fell GS. 1993: Comparison of control of serum phosphate levels during continuous amnulatory peritoneal dialysis and during hemodialysis. *Perit dial Bull*. 3:97-98.
 - Cansick J, Waller S, Ridout D, Rees L. 2007: Growth and PTH in prepubertal children on long-term dialysis. *Pediatr Nephrol*. 22:1349–54.
 - Capeillère-Blandin C, Gausson V, Descamps-Latscha B, Witko-Sarsat V. 2004: Biochemical and spectrophotometric significance of advanced oxidized protein products. *Biochim Biophys Acta*. 1689:91-102.
 - Chertow GM, Kurella M, Lowrie EG. 2006: The tortoise and hare on hemodialysis: does slow and steady win the race? *Kidney Int*. 70:24-25.
-

-
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al., 2003: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. May 21 ;289(19):2560-72.
 - Clarke, B. 2008: “Normal bone anatomy and physiology”, Clinical journal of the American Society of Nephrology : CJASN, vol. 3 Suppl 3, pp. S131-9.
 - Coburn JW, Tan AU Jr, Levine BS. 1996: 1 α -hydroxyvitamin D2: a new look at an “old” compound. Nephrol dial transplant. 11:153-157.
 - Cohen-Solal, Sebert JL, Boudailliez B. 1991: Comparison of intact, midregion, and carboxy-terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab. 73:516-524.
 - Compston, J.E. 2001: “Sex steroids and bone”, Physiological Reviews, vol. 81, no. 1, pp. 419-447.
 - Conger JD, Hammond WS, Altery AC. 1995: Pulmonary calcification in chronic dialysis patients. Clinical and pathologic studies. Ann Intern Med. 83:330-336.
 - Coresh J, Astor BC, Greene T, et al., 2003: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 41(1):1-12.
 - Coresh J, Byrd-Holt D, Astor BC, et al., 2005: Chronic kidney disease awareness, prevalence, and trends among U.S. adults. J Am Soc Nephrol 16:180-188.
 - Coresh J, Selvin E, Stevens LA, et al., 2007: Prevalence of chronic kidney disease in the United States. JAMA.298(17):2038-47.
 - Courteix, D., Lespessailles, E., Peres, S.L., Obert, P., Germain, P. & Benhamou, C.L. 1998: “Effect of physical training on bone mineral density in prepubertal girls: a comparative study between impact-loading and non-impact-loading sports”, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 8, no. 2, pp. 152-158.
 - Courteix, D., Jaffre, C., Lespessailles, E. & Benhamou, L. 2005: “Cumulative effects of calcium supplementation and physical activity on bone accretion in premenarchal children: a double-
-

-
- blind randomised placebo-controlled trial”, *International Journal of Sports Medicine*, vol. 26, no. 5, pp. 332-338.
- Cunningham J, Coldwell RD. 1992: Dialysate calcium reduction in CAPD patients treated with calcium carbonate and α -calcidiol. *Nephrol Dial Transplant*. 7:63-68.
 - Davids JR, Fisher R, Lum G. 1992: Angular deformity of the lower extremity in children with renal osteodystrophy. *J Pediatr Orthop*. 12:291-299.
 - Dawson-Hughes, B. & Bischoff-Ferrari, H.A. 2007: “Therapy of osteoporosis with calcium and vitamin D”, *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, vol. 22 Suppl 2, pp. V59-63.
 - Dawson-Hughes, B., Heaney, R.P., Holick, M.F., Lips, P., Meunier, P.J. & Vieth, R. 2005: “Estimates of optimal vitamin D status”, *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*, vol. 16, no. 7, pp. 713-716.
 - De Deyn PP, D'Hooge R, Van Bogaert PP, Marescau B. 2001: Endogenous guanidino compounds as uremic neurotoxins. *Kidney Int Suppl*. 78:S77-S83.
 - Deeb, K.K, Trump, D.L. & Johnson, C.S. 2007: “Vitamin D signalling pathways in cancer: potential for anticancer therapeutics”, *Nature Reviews Cancer*, vol. 7, no. 9, pp. 684-700.
 - Dember LM, Jaber BL. 2006: Dialysis-related amyloidosis: late finding or hidden epidemic? *Semin Dial*. 19:105-109.
 - Demircin G, Oner, A, Ecin N, Bulbul M, Somuncu I, Tunali H. 1998: Microfocal radiography in the diagnosis of childhood renal osteodystrophy. *Acta Paediatr Jpn*. 40(5):461-5.
 - Demster, D.W. 2006: Anatomy and Functions of the Adult skeleton in *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, Sixth edn, The American Society for Bone and Mineral Research, Washington D.C. pp. 7-11.
 - Depner TA. 2001: Uremic toxicity: urea and beyond. *Semin Dial*. 14:246-251.
 - Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A. 2006: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N Engl J Med* 355: 2071–2084.
-

-
- Drueke TB. 1999: Abnormal skeletal response to parathyroid hormone and the expression of its receptor in chronic uremia. *Pediatr Nephrol* 13(3):348-50.
 - Eknoyan G, Beck GJ, Cheung AK, et al., 2002: Effect of dialysis dose and membrane flux in maintenance hemodialysis. *N Engl J Med*. 347:2010-2019.
 - Eloot S, Torremans A, De Smet R, et al., 2005: Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds. *Kidney Int*.67:1566-1575.
 - ESPN (European Society for Paediatric Nephrology). 2002: ESPN Handbook. Lyon, France: Medcom; 461.
 - FDA Alert,2007: Erythropoiesis Stimulating Agents (ESA). Rockville, MD, U.S. Food and Drug Administration.
 - Felsenfeld AJ, Liach F. 1993: Parathyroid gland function in chronic renal failure. *Kidney Int*. 43:771-789.
 - Fournier A, Oprisiu R, Hottelart C, Yverneau PH, Ghazali A, Atik A, Hedri H, Said S, Sechet A, Rasolombololona M, Abighanem O, Sarraj A, El-Esper N, Moriniere P, Boudailliez B, Westeel PF, Achard JM, Pruna A. 1998: Renal osteodystrophy in dialysis patients: diagnosis and treatment. *Artif Organs*. 22(7): 530-57.
 - Frost, H.M. & Schonau, E. 2000: “The “muscle-bone unit” in children and adolescents: a 2000 overview”, *Journal of pediatric endocrinology & metabolism : JPEM*, vol. 13, no. 6, pp. 571-590.
 - Fukuda N, Tanaka H, Tominaga Y. 1993: Decreased 1,25-dihydrovitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. *J Clin Invest*. 92:1436-1443.
 - Galceran T, Martin KJ, Morrissey JJ. 1987: The role of 1,25(OH)2D3 on the pathogenesis of skeletal resistance to parathyroid hormone in chronic renal failure. *Kidney Int*. 32: 80 1-807.
 - Gal-Moscovici A , Popovtzer MM. 2005: New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. *Clin Nephrol*. 63: 284–9.
 - Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, Zelikovsky N, Fivush B, Furth S. 2004: Anemia and health-related quality of life in adolescents with chronic kidney disease. *Am J Kidney Dis* 44: 1017–1023.
-

-
- Gipstein RM, Coburn JW, Adams JA. 1986: Calciphylaxis in man: a syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. *Arch Intern Med.* 136:1273-1280.
 - Gogusev J, Duchambon P, Hory B. 1997: Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. *Kidney Int.* 51:328-336.
 - Gonzalez E, Schomberg J, Amin N, Salusky IB, Zaritsky J. 2010: Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. *Pediatr Nephrol.* Feb;25(2):373-5.
 - Goodman WG, Salusky IB. 1991: Evolution of secondary hyperparathyroidism during daily oral calcitriol therapy in pediatric renal osteodystrophy. *Contrib Nephrol.* 90:189-195.
 - Goodman WG, Ramirez JA, Beli TR. 1994: Development of adynamic bone in patients with secondary hyperparathyroidism on intermittent calcitriol therapy. *Kidney Int.* 46:1 160-1166.
 - Goodman WG, Veidhuis JD, Belin TR, Juppner H, Salusky IB. 1997: Suppressive effect of calcium on parathyroid hormone release in adynamic renal osteodystrophy and secondary hyperparathyroidism. *Kidney Int.* 51(5):1590-5.
 - Goulding, A., Cannan, R., Williams, S.M., Gold, E.J., Taylor, R.W. & Lewis-Barned, N.J. 1998: "Bone mineral density in girls with forearm fractures", *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, vol. 13, no. 1, pp. 143-148.
 - Griva K, Thompson D, Jayasena D, Davenport A, Harrison M, Newman SP. 2006: Cognitive functioning pre- to post-kidney transplantation -- a prospective study. *Nephrol Dial Transplant* 21:3275-3282.
 - Guerin A, London G, Marchais S. 1985: Acute deafness and desferrioxamine. *Lancet* .2:39-40
 - Haapasalo, H., Kannus, P., Sievänen, H., Pasanen, M., Uusi-Rasi, K., Heinonen, A., Oja, P. & Vuori, I. 1998: "Effect of long-term unilateral activity on bone mineral density of female junior tennis players", *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, vol. 13, no. 2, pp. 310-319.
 - Haffner D, Nissel R. 2008: Growth and puberty in chronic kidney disease. In: Geary DF, Schaefer F (eds) *Comprehensive pediatric nephrology*. Elsevier, Philadelphia, pp S709–S732.
-

-
- Hailpern SM, Melamed ML, Cohen HD, Hostetter TH. 2007: Moderate kidney disease and cognitive function in adults 20-59 years of age. *J Am Soc Nephrol.* 18:2205-2213.
 - Hanly PJ, Pierratos A. 2001: Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. *N Engl J Med.* 344:102-107.
 - Hasselstrom, H., Karlsson, K.M., Hansen, S.E., Gronfeldt, V., Froberg, K. & Andersen, L.B. 2007: "Peripheral bone mineral density and different intensities of physical activity in children 6-8 years old: the Copenhagen School Child Intervention study", *Calcified tissue international*, vol. 80, no. 1, pp. 31-38.
 - Heaney, R.P., Abrams, S., Dawson-Hughes, B., Looker, A., Marcus, R., Matkovic, V. & Weaver, C. 2000: "Peak bone mass", *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*, vol. 11, no. 12, pp. 985-1009.
 - Heaney, R.P., Dowell, M.S., Hale, C.A. & Bendich, A. 2003: "Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D", *Journal of the American College of Nutrition*, vol. 22, no. 2, pp. 142-146.
 - Heaney R.P. 2007: "Bone health", *The American Journal of Clinical Nutrition*, vol. 85, no. 1, pp. 300S-303S.
 - Henderson RG, Ledingham JGG, Oliver DO. 1984: Effects of 1,25-dihydrocholecalciferol on calcium absorption, muscle weakness and bone disease in chronic renal failure. *Lancet.* 1:379-388.
 - Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. 2002: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. *Kidney Int.* 62:1524-1538.
 - Hodsman AB, Sherrard DJ, Alfrey AC. 1982: Bone aluminum and histomorphometric features of renal osteodystrophy. *J Clin Endocrinol Metab.* 54:539-546.
 - Hofbauer L, Khosla S, Dunstan C, Lacey L, Boyle W & Riggs B. 2000: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. *Journal of Bone and Mineral Research.* 15: 2-12.
 - Hofbauer, L.C. & Schoppet, M. 2004: "Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular
-

diseases”, JAMA : the journal of the American Medical Association, vol. 292, no. 4, pp. 490-495.

- Hogg RJ, Furth S, KV L, et al. 2003: National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. *Pediatrics*.111:1416.
- Holick M.F. 2003: “Vitamin D: A millenium perspective”, *Journal of cellular biochemistry*, vol. 88, no. 2, pp. 296-307.
- Holick M.F. 2007: “Vitamin D deficiency”, *The New England journal of medicine*, vol. 357, no. 3, pp. 266-281.
- Jafar TH, Schmid CH, Landa M, et al. 2001: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. *Ann Intern Med*.135(2):73-87.
- Jarava C, Annas JR, Slogueira M. 1996: Bone alkaline phosphatase isoenzyme in renal osteodystrophy. *Nephrol Dial Transplant*. 11(Suppl 3): 43-46.
- Joffe P and Podenpha 1989: Bone histology in CAPD patients: a comparison with hemodialysis and conservatively treated chronic uremics. *Adv Pent Dial*. 5:171-176.
- Johnson WJ, Hagge WW, Wagoner RD, Dinapoli RP, Rosevear JW. 1972: Effects of urea loading in patients with far-advanced renal failure. *Mayo Clin Proc*. 47:21-29.
- Jones, G., Riley, M.D. & Dwyer, T. 2000: “Maternal diet during pregnancy is associated with bone mineral density in children: a longitudinal study”, *European journal of clinical nutrition*, vol. 54, no. 10, pp. 749-756.
- Kardinaal, A.F., Ando, S., Charles, P., Charzewska, J., Rotily, M., Vaananen, K., Van Erp-Baart, A.M., Heikkinen, J., Thomsen, J., Maggiolini, M., Deloraine, A., Chabros, E., Juvin, R. & Schaafsma, G. 1999: “Dietary calcium and bone density in adolescent girls and young women in Europe”, *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, vol. 14, no. 4, pp. 583-592.
- Kato, T., Yamashita, T., Mizutani, S., Honda, A., Matumoto, M. & Umemura, Y. 2009: “Adolescent exercise associated with long-term superior measures of bone geometry: A cross-sectional DXA and MRI study”, *British journal of sports medicine*, Jan 5.

-
- KDIGO. 2009: Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Guideline 1: Introduction and definition of CKD-MBD and the development of the guideline statements. *Kidney International*: 76, S3-S8.
 - KDOQI. 2007: clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. *Am J Kidney Dis* 50: 471–530.
 - Khosla, S., Melton, L.J., 3rd & Riggs, B.L. 2002: “Clinical review 144: Estrogen and the male skeleton”, *The Journal of clinical endocrinology and metabolism*, vol. 87, no. 4, pp. 1443-1450.
 - Kifor O, Moore FD Jr, Wang P 1996: Reduced immunostaining for the extracellular Ca^{++} sensing receptor in primary and uremic secondary hyperparathyroidism. *J Clin Endocrinol Metab.* 81:1598-1606.
 - Kirkwood JR, Ozonoff MB, Steinbeck HL. 1998: Epiphyseal displacement after metaphyseal fracture in renal osteodystrophy. *Am J Radiol.* 115:547-554.
 - Klaus G, Watson A, Edefonti A, Fischbach M, Rönnholm K, Schaefer F, Simkova E, Stefanidis CJ, Strazdins V, Vande Walle J, Schröder C, Zurowska A, Ekim M. 2006: Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. *Pediatr Nephrol.* February; 21(2): 151–159.
 - Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. 2005: Insulin resistance in patients with chronic kidney disease. *Am J Kidney Dis.* 45:275-280.
 - Komiyama Y, Dong XH, Nishimura N, et al., 2005: A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. *Clin Biochem.* 38:36-45.
 - Kooienga L, Moor R. 2008: Sevelamer carbonate in the management of hyperphosphatemia. *Therapy*; July; 5(4): 545-552.
 - Kopple JD, Greene T, Chumlea WC, et al., 2000: Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. *Kidney Int.* 57:1688-1703.
-

-
- Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Bostock H, Kiernan MC. 2000: Altered motor nerve excitability in end-stage kidney disease. *Brain* .128:2164-2174.
 - Kröger, H., Kotaniemi, A., Kröger, L. & Alhava, E. 1993: “Development of bone mass and bone density of the spine and femoral neck--a prospective study of 65 children and adolescents”, *Bone and mineral*, vol. 23, no. 3, pp. 171-182.
 - Kuizon BD, Goodman WG, Juppner H, Boechat I, Nelson P, Gales B, Salusky IB. 1998: Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. *Kidney Int* 53:205–211.
 - Kuizon BD and Salusky IB. 1999: Growth retardation in children with chronic renal failure. *Journal Of Bone And Mineral Research*. 14(10):1680-1690.
 - Kuizon BD, Salusky IB. 2002: Cell biology of renal osteodystrophy. *Pediatr Nephrol* 17:777–789.
 - Kurz P, Monier-Faugere MC, Bogner B, Werner E, Roth P, Vlachojannis J, Malluche HH. 1994: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. *Kidney Int* 46: 855–861.
 - Kwan JTC, Almond MK, Beer JC. 1992: Pulse oral calcitriol in uremic patients: rapid modification of parathyroid response to calcium. *Nephrol Dial Transplant*. 7:829-834.
 - Lauridsen, A.L., Vestergaard, P., Hermann, A.P., Brot, C., Heickendorff, L., Mosekilde, L. & Nexø, E. 2005: “Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women”, *Calcified tissue international*, vol. 77, no. 1, pp. 15-22.
 - Lee PDK, Hintz RL, Sperry JB. 1989: Insulin growth factor binding proteins in growth retarded children with chronic renal failure. *Pediatr Res*. 26:308-315.
 - Levey AS, Coresh J, Balk E, et al., 2003: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med*. 139(2):137-47.
 - Liach F, Massry SG. 1985: On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. *J Clin Endocrinol Metab*. 61:601-606.
 - Lips P. 2006: “Vitamin D physiology”, *Progress in biophysics and molecular biology*, vol. 92, no. 1, pp. 4-8.
-

-
- Mailloux LU. 2001: Hypertension in chronic renal failure and ESRD: prevalence, pathophysiology, and outcomes. *Semin Nephrol.*21(2):146-56.
 - Malluche RH, Ritz E, Lange HP. 1980: Bone histology in incipient and advanced renal failure. *Kidney Int.* 9: 355-362.
 - Malluche HH, Smith AJ, Abreo K. 1984: The use of deferoxamine in the management of aluminum accumulation in bone in patients with renal failure. *N Eng J Med.* 311:140-144.
 - Malluche HH. 1986: *Atlas of Mineralized Bone Histology.* New York, Karger.
 - Malluche HH, Moniere-Faugere MC. 1992: Risk of adynamic bone disease in dialyzed patients. *Kidney Int.* 42: S62- S67.
 - Malluche HH, Monier-Faugere MC. 2006: Renal osteo-dystrophy: What's in a name? Presentation of a clinically useful new model to interpret bone histologic findings. *Clin Nephrol* 65(4): 235-42.
 - Malluche HH, Monier-Faugere MC, Wang G, et al., 2008: An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. *Clin Nephrol* ;69(4):269-78.
 - Maniar S, Kleinknecht C, Zhou X. 1996: Growth hormone action is blunted by acidosis in experimental uremia on acid load. *Clin Nephrol.* 46:72-76.
 - Mankin HJ. 1990: Rickets, osteomalacia and renal osteodystrophy - an update. *Orthop Clin North Am.* 21(1):81-96.
 - Martin KJ, González EA. 2007: Metabolic bone disease in chronic kidney disease. *J Am Soc Nephrol.*;18(3):875-85.
 - Martin KJ, Olgaard K, Coburn JW, et al., 2004: Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. *Am J Kidney Dis.*43(3):558-65.
 - Martinez AW, Recht NS, Hostetter TH, Meyer TW. 2005: Removal of p-cresol sulfate by hemodialysis. *J Am Soc Nephrol.* 16:3430-3436.
 - Maschio G, Oldrezzi L, Tessitore N. 1982: Effects of dietary and protein restriction on the progression of early renal failure. *Kidney Int.* 22:37 1-376. Milliner DS, Hercz G, Miller JH. 1986: Clearance of aluminum by hemodialysis: Effect of deferoxamine. *Kidney Int.* 29(Suppl 18): S100-S103.
 - McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M. 2004: The prevalence of anemia in patients with chronic kidney disease. *Curr Med Res Opin* 20: 1501–1510.
-

-
- Mehls O. 1984: Renal osteodystrophy in children , Etiology and clinical aspects. In: Fine RN, Gruskin AB, eds. End Stage Renal Disease in Children. Philadelphia: WB Saunders. 227-250.
 - Mehls O, Ritz E, Krempien B. 1985: Slipped epiphyses in renal osteodystrophy. Arch Dis Child. 50:545.
 - Meyer TW, Leeper EC, Bartlett DW, et al., 2004: Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes. J Am Soc Nephrol.15:1927-1935.
 - Meyer TW and Hostetter TH. Uremia. 2007: 357(13):1316-1325.
 - Milliner DS, Nebeker HG, Ott SM. 1984: Use of the deferoxamine infusion test in the diagnosis of aluminum related osteodystrophy. Ann Intern Med. 101:775-779.
 - Milliner DS, Zinsmeister AR, lieberman E. 1990: Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int. 38:931-936.
 - Miyata T, Sugiyama S, Saito A, Kurokawa K. 2001: Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int Suppl.78:S25-S31.
 - Moe, N. & Rygg, M. 1998: "Epidemiology of juvenile chronic arthritis in northern Norway: a ten-year retrospective study", Clinical and experimental rheumatology, vol. 16, no. 1, pp. 99-101.
 - Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. 2006: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945–1953.
 - Mucsi I, Molnar MZ, Ambrus C, et al., 2005: Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis. Nephrol Dial Transplant. 20:571-577.
 - Murphy, S., Khaw, K.T., May, H. & Compston, J.E. 1994: "Milk consumption and bone mineral density in middle aged and elderly women", BMJ (Clinical research ed.), vol. 308, no. 6934, pp. 939-941.
 - Murray AM, Tupper DE, Knopman DS, et al., 2006: Cognitive impairment in hemodialysis patients is common. Neurology. 67:216-223.
 - National Kidney Foundation. 2002: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 39(2 Suppl 1):S1-266.
-

-
- Neer, R.M., Arnaud, C.D., Zanchetta, J.R., Prince, R., Gaich, G.A., Reginster, J.Y., Hodsman, A.B., Eriksen, E.F., Ish-Shalom, S., Genant, H.K., Wang, O. & Mitlak, B.H. 2001: “Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis”, *The New England journal of medicine*, vol. 344, no. 19, pp. 1434-1441.
 - Nemeth EF. 1995: Ca²⁺ receptor-dependent regulation of cellular functions. *News Physiol Sci*. 10:1-5
 - NKF/DOQI. 2005: Clinical Practice guidelines for bone metabolism and disease in children with chronic kidney disease. *Am J Kidney Dis*. 46(Suppl 1).
 - Norden AG, Sharratt P, Cutillas PR, Cramer R, Gardner SC, Unwin RJ. 2004: Quantitative amino acid and proteomic analysis: very low excretion of polypeptides >750 Da in normal urine. *Kidney Int* .66:1994-2003.
 - Norman LJ, Coleman JE, Macdonald I, Tomsett A, Watson AR. 2000: Nutrition and growth in relation to severity of renal disease in children. *Pediatr Nephrol*. 14:833–836.
 - Nurmi-Lawton, J.A., Baxter-Jones, A.D., Mirwald, R.L., Bishop, J.A., Taylor, P., Cooper, C. & New, S.A. 2004: “Evidence of sustained skeletal benefits from impact- loading exercise in young females: a 3-year longitudinal study”, *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, vol. 19, no. 2, pp. 314-322.
 - Nussbaum SR, Zahradnik RI, Lavigne JR. 1987: Highly-sensitive two site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. *Clin Chem*.33:1364-1367.
 - Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F. 2006: Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. *Circulation* ;106:100–105.
 - Ott SM, Maloney NA, Coburn JW. 1982: The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. *N Engl J Med*. 307:709-713.
 - Ott SM, Andress DL, Nebeker HG. 1986: Changes in bone histology after treatment with desferrioxamine. *Kidney Int*. 29(Suppl 18): S108-S113.
 - Paoletti E , Cannella G.2006: Update on erythropoietin treatment: Should hemoglobin be normalized in patients with chronic kidney disease? *J Am Soc Nephrol* 17: S74–S77.
-

-
- Parisien M, Charhon SA, Arlot M. 1988: Evidence for a toxic effect of aluminum on osteoblasts: A histomorphometric study in hemodialysis patients with aplastic bone disease. *J Bone Miner Res.* 3:259-267.
 - Park CH, Park HD, Lee SY, Kim JW, Sohn YB, Park SW, Jin DK. 2010: Clinical, biochemical, and genetic analysis of Korean patients with pseudohypoparathyroidism type Ia. *Ann Clin Lab Sci.* 40(3):261-6.
 - Patel SR, Ke HQ, Hsu CH. 1994: Effect of vitamin D metabolites on calcitriol degradative enzymes in renal failure. *Kidney Int.* 45:509-514.
 - Pei Y, Hercz G, Greenwood C, Segre GV, Manuel A, Saiphoo C, Fenton S, Sherrard DJ. 1995: Risk factors for renal osteodystrophy: A multivariate analysis. *J Bone Miner Res* 10: 149–156.
 - Pena YT, Soyibo AK, McGrowder D, Clarke TR, Barton EN. 2010: The importance of bone biomarkers in the diagnosis of renal osteodystrophy. *West Indian Med J.* 59(3):332-7.
 - Perl J, Unruh ML, Chan CT. 2006: Sleep disorders in end-stage renal disease: 'Markers of inadequate dialysis'? *Kidney Int.* 70:1687-1693.
 - Perlman RL, Finkelstein FO, Liu L, et al., 2005: Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. *Am J Kidney Dis.* 45:658-666.
 - Pirisino R, Ghelardini C, De Siena G, et al., 2005: Methylamine: a new endogenous modulator of neuron firing? *Med Sci Monit.* 11:RA257-61.
 - Polito C, Greco L, Tettoni SF. 1987: Statural growth of children with chronic renal failure on conservative treatment. *Acta Paediatr Scand.* 76:97-102.
 - Potts, J.T. 2005: "Parathyroid hormone: past and present", *The Journal of endocrinology*, vol. 187, no. 3, pp. 311-325.
 - Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. 2005: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. *J Am Soc Nephrol.* 16:2449-2455.
 - Reichel H, Deibert B, Schmidt-Gayk H. 1991: Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. *Nephrol Dial transplant.* 6:162-169.
-

-
- Rigalleau V, Gin H. 2005; Carbohydrate metabolism in uraemia. *Curr Opin Clin Nutr Metab Care*. 8:463-469.
 - Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI. 2005: Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time. *Kidney Int* 68: 2323–2330.
 - Ruiz, J.C., Mandel, C. & Garabedian, M. 1995: “Influence of spontaneous calcium intake and physical exercise on the vertebral and femoral bone mineral density of children and adolescents”, *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, vol. 10, no. 5, pp. 675-682.
 - Runowski D, Piatkowska Kopczyk M, Zachwieja J, Nikias A, Maciejewski J. 2001: Multiple bone fractures as a complication in a child with chronic renal failure. *Pol-merkurusz-Lek*. 10(5 8):294-5.
 - Saggese, G., Bertelloni, S. & Baroncelli, G.I. 1997: “Sex steroids and the acquisition of bone mass”, *Hormone research*, vol. 48 Suppl 5, pp. 65-71.
 - Salusky TB, Coburn JW, Paunier L. 1984: Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysis. *J Pediatr*. 105:717-720.
 - Salusky IB, Coburn JW, Foley J. 1986: Effects of oral calcium carbonate on control of serum phosphorus and change in plasma aluminum levels after discontinuation of aluminum containing gels in children receiving dialysis. *J Pediatr*. 108:767-770.
 - Salusky IB, Coburn JW, Brill J. 1988: Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. *Kidney Int*. 33:975-982.
 - Salusky IB, Foley J, Nelson P. 1991: Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. *N Engl J Med*. 324:527-531.
 - Salusky IB, Ramirez JA, Oppenheim WL, Gales B, Segre GV, Goodman WG. 1994: Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. *Kidney Int* 45: 253– 258.

-
- Saluskya IB, Kuizona BG, Jüppnerb H. 2004: Special aspects of renal osteodystrophy in children. *Seminars in Nephrology*; 24(1): 69-77.
 - Sanchez CP. 2001: Prevention and treatment of renal osteodystrophy in children with chronic renal insufficiency and end-stage renal disease. *Semin-Nephrol.* 21(5): 411-50.
 - Sanchez C.P. 2008: “Mineral metabolism and bone abnormalities in children with chronic renal failure”, *Reviews in endocrine & metabolic disorders*, vol. 9, no. 2, pp. 131-137.
 - Sanchez CP and Salusky IB 1996: The renal bone diseases in children treated with dialysis. *Adv-Ren-Replace-Ther.* 3(1):14-23.
 - Sanchez CP, Salusky TB, Kuizon BD. 1997: Calcitriol modifies the response to growth hormone in rats with secondary hyperparathyroidism (Abstract). *J Am Soc Nephrol.* 8:580A.
 - Sanna-Cherchi S, Ravani P, Corbani V, Parodi S, Haupt R, Piaggio G, Innocenti ML, Somenzi D, Trivelli A, Caridi G, et al. 2009: Renal outcome in patients with congenital anomalies of the kidney and urinary tract. *Kidney Int.* 76:528–533.
 - Schaefer K, Sheer J, Asmus G. 1991: The treatment of uremic hyperphosphatemia with calcium acetate and calcium carbonate: a comparative study. *Nephrol Dial Transplant.* 6:171-175.
 - Schaefer K, Umlauf E, von-Herrath D. 1992: Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night. *Am J Kidney Dis.* 19:460-464.
 - Schneditz D, Daugirdas JT. 2001: Compartment effects in hemodialysis. *Semin Dial.* 14:271-277.
 - Schwartz GJ, Furth S, Cole SR, Warady B, Munoz A. 2006: Glomerular filtration rate via plasma iothexol disappearance: pilot study for chronic kidney disease in children. *Kidney Int.* 69:2070–2077.
 - Schwartz GJ, Work DF. 2009: Measurement and Estimation of GFR in Children and Adolescents. *CJASN* November vol. 4 no. 11 1832-1843.
 - Sedman AB, Miller NL, Warady BA. 1984: Aluminum loading in children with chronic renal failure. *Kidney Int.* 26:201-204.
 - Segersten, U., Correa, P., Hewison, M., Hellman, P., Dralle, H., Carling, T., Åkerstrom, G. & Westin, G. 2002: “25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal
-

-
- and pathological parathyroid glands”, *The Journal of clinical endocrinology and metabolism*, vol. 87, no. 6, pp. 2967-2972.
- Sherrard DJ, Ott SM, Maloney NA. 1984: Uremic osteodystrophy: classification, cause and treatment. In: Frame B, Potts J, eds. *Proceedings of the symposium on Clinical Disorders of Bone and Mineral Metabolism*. Amsterdam: Excerpta Medica. 254-259.
 - Silver J, Naveh-Many T, Mayer H. 1996: Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. *J Clin Invest*. 78: 1298-1301.
 - Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. 2006: Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med* 355: 2085–2098.
 - Slatopolsky E, Finch J, Denda M. 1996: Phosphorus restriction prevents parathyroid gland growth. *J Clin Invest*. 97:2534-2540.
 - Somjen, D., Weisman, Y., Kohen, F., Gayer, B., Limor, R., Sharon, O., Jaccard, N., Knoll, E. & Stern, N. 2005: “25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds”, *Circulation*, vol. 111, no. 13, pp. 1666-1671.
 - Soroko, S., Holbrook, T.L., Edelstein, S. & Barrett-Connor, E. 1994: “Lifetime milk consumption and bone mineral density in older women”, *American Journal of Public Health*, vol. 84, no. 8, pp. 1319-1322.
 - Sprague SM. 2000: The role of the bone biopsy in the diagnosis of renal osteodystrophy. *Semin Dial* ;13(3):152-5.
 - Staples AO, Smith JC, Gipson DS, Wong CS, Filler G, Warady B, Martz K, Greenbaum LA. 2007: Risk factors associated with progression of pediatric chronic kidney disease. *E-PAS* 2007:61:7919.5.
 - Sultana S, Rahman MH, Paul SK, Hossain MM. 2007: Impact of etiology of chronic renal failure on growth in children. *Mymensingh Med J*. 16(2 Suppl):S34-39.
 - Teegarden, D., Lyle, R.M., Proulx, W.R., Johnston, C.C. & Weaver, C.M. 1999: “Previous milk consumption is associated with greater bone density in young women”, *The American Journal of Clinical Nutrition*, vol. 69, no. 5, pp. 1014- 1017.
-

-
- Tenbrock K, Kruppa S, Mokov E, Querfeld U, Michalk D, Schoenau E. 2000: Analysis of muscle strength and bone structure in children with renal disease. *Pediatr-Nephrol.* 14(7): 669-72
 - Tonshoff B, Mehls O, Heinrich U. 1990: Growth-stimulation effects of recombinant human growth hormone in children with end-stage renal disease. *J Pediatr.* 116:561-566.
 - Trofimov S, Pantsulaia Ia, Kobylansky E and Livshits G. 2004: Circulating levels of receptor activator of nuclear factor- κ B ligand/ osteoprotegerin/ macrophage-colony stimulating factor in a presumably human population. *European Journal of Endocrinology.* 150: 305- 311.
 - United States Renal Data System (USRDS) 2004: Annual Data Report. Bethesda, MD: The National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases. S39-361.
 - USRDS. 2006: annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: U.S. Renal Data System, 12:323-329.
 - Välimäki, V.V., Alfthan, H., Lehmuskallio, E., Löyttyniemi, E., Sahi, T., Stenman, U.H., Suominen, H. & Välimäki, M.J. 2004: "Vitamin D status as a determinant of peak bone mass in young Finnish men", *The Journal of clinical endocrinology and metabolism*, vol. 89, no. 1, pp. 76-80.
 - Vanholder R, De Smet R, Glorieux G, et al. 2003: Review on uremic toxins: classification, concentration, and interindividual variability. *Kidney Int.* 63:1934-1943.
 - Vassalotti JA, Stevens LA, Levey AS. 2007: Testing for chronic kidney disease: a position statement from the national kidney foundation. *Am J Kidney Dis.* 50:169–180.
 - Veis JH, Contiguglia R, Klein M. 1987: Mucormycosis in deferoxamine treated patients on dialysis. *Ann Intern Med.* 107:258.
 - Verroust PJ, Birn H, Nielsen R, Kozyraki R, Christensen EI. 2002: The tandem endocytic receptors megalin and cubilin are important proteins in renal pathology. *Kidney Int.* 62:745-756.
 - Viljakainen, H.T., Natri, A.M., Kärkkäinen, M., Huttunen, M.M., Palssa, A., Jakobsen, J., Cashman, K.D., Molgaard, C. & Lamberg-Allardt, C. 2006: "A positive dose-response effect of
-

-
- vitamin D supplementation on site-specific bone mineral augmentation in adolescent girls: a double-blinded randomized placebo- controlled 1-year intervention”, *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, vol. 21, no. 6, pp. 836-844.
- Wada M, Tshii H, Furuay Y.1998: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. *Kidney Int.* 53:448-453
 - Waller S. 2011: Parathyroid hormone and growth in chronic kidney disease. *Pediatr Nephrol.* Feb 26(2):195-204.
 - Waller SC, Ridout D, Cantor T, Rees L. 2005: Parathyroid hormone and growth in children with chronic renal failure. *Kidney Int.* 67:2338–45.
 - Walsh MC, Choi Y. 2003: Biology of the TRACE axis. *Cytokine and Growth Factor. Reviews.* 14:51-63.
 - Wang, M.C., Crawford, P.B., Hudes, M., Van Loan, M., Siemering, K. & Bachrach, L.K. 2003: “Diet in midpuberty and sedentary activity in prepuberty predict peak bone mass”, *The American Journal of Clinical Nutrition*, vol. 77, no. 2, pp. 495-503.
 - Warady BA, Hebert D, Sullivan EK. 1997: Renal transplantation, chronic dialysis, and chronic renal insufficiency in children and adolescents. *Pediatr Nephrol.* 11:49-64.
 - Warady BA, Ho M.2003: Morbidity and mortality in children with anemia at initiation of dialysis. *Pediatr Nephrol* 18: 1055–1062.
 - Watson AR, Gartland C. 2001: European Paediatric Peritoneal Dialysis Working Group Guidelines by an Ad Hoc European Committee for Elective Chronic Peritoneal Dialysis in Pediatric Patients. *Perit Dial Int .* 21:240–244.
 - Weissinger EM, Kaiser T, Meert N, et al., 2004: Proteomics: a novel tool to unravel the patho-physiology of uraemia. *Nephrol Dial Transplant.* 19:3068-3077.
 - Wesseling, K., Bakkaloglu, S. & Salusky, I. 2008, ”Chronic kidney disease mineral and bone disorder in children”, *Pediatric Nephrology*, vol 23, no. 2, pp 195-207.
 - Wharton, B. & Bishop, N. 2003: “Rickets”, *Lancet*, vol. 362, no. 9393, pp. 1389- 1400.
 - Wong H, Mylrea K, Feber J, Drukker A, Filler G. 2006: Prevalence of complications in children with
-

chronic kidney disease according to KDOQI. *Kidney Int* 70: 585–590.

- Wong CS, Mak RHK. 2007: Chronic kidney disease. In: Kher KK, Schnapper HW, Makker SP, editors. *Clinical Pediatric Nephrology*. Informa UK Ltd. pp. 339–352.
- Wright RS, Mehis O, Ritz E. 1982: Musculoskeletal manifestations of chronic renal failure, dialysis and transplantation. In: Bacon P, Hadler N, eds. *Renal Manifestations In Rheumatic Disease*. London: Butterworth. 352.
- Wuhl E, Hoffner D, Nissel R. 1996: Short dialyzed children respond less to growth hormone than patients prior to dialysis. *Pediatr Nephrol*. 10:294-298.
- Xue JL, Ma JZ, Louis TA, et al. 2001: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. *J Am Soc Nephrol*. Dec 12(12):2753-8.
- Yalcinkaya F, Ince E, Turner N, Ensari A, Ozkaya N. 2000: Spectrum of renal osteodystrophy in children on continuous ambulatory peritoneal dialysis. *Pediatr-Int*. 42(1): 53-7.
- Yalcinkaya F, Ince E, Tumer N, Ensari A, Ozkaya N. 2000: Spectrum of renal osteodystrophy in children on continuous ambulatory peritoneal dialysis. *Pediatr Int*. 42: 53- 57.
- Ziolkowska H, Panczyk-Tomaszewska M, Deninski A, Materna B, Przedlacki J, Sawicki A, Roszkowska-Blaim 2000: Risk factors of adynamic bone disease in children with end-stage renal failure: personal experience. *Pol-merkuriusz-led*. 8(46): 262-3.
- Ziolkowska H, Paniczyk-Tomaszewska M, Debinski A, Polowiec Z, Sawicki A, Sieniawska M. 2000: Bone biopsy results and serum bone turnover parameters in uremic children. *Acta Paediatr*. 89: 666-671.
- Zoccali C. 2006: Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. *Kidney Int*. 70:26-33.

Master sheet for the patients:

NO.	Sex	Age	Weight	Height	BP Sys	BP Dias	BUN	Creatinine	Sodium	Potassium
1	Male	10	24	110	110	70	87	4.6	138	4.9
2	Male	16	45.5	166	125	70	116	5.9	139	5,4
3	Male	12	31	113	140	100	177	10.9	132	5.1
4	Female	14	38	115	120	80	128	7.5	143	4.5
5	Male	8	19.5	99	130	90	95	6.4	151	3.2
6	Male	13	37	144	110	70	131	7.7	132	4.9
7	Male	12	24	104	90	60	110	6.7	141	5
8	Male	14	32	109	145	85	202	6.8	133	4.7
9	Female	15	38	135	100	70	84	5.8	139	5.1
10	Male	16	43	143	100	70	148	11.37	130	4.78
11	Male	7	18	106	110	60	104	7.7	159	5.1
12	Female	9.5	22	111	110	80	64	2.4	178	5.3
13	Male	13.5	47	142	130	90	85	9.4	160	5.1
14	Male	9.5	27	109	110	70	96	4.7	177	4.1
15	Male	13	29	126	120	70	242	7.2	164	6.2
16	Female	7	20.5	112	110	70	148	6.8	132	4
17	Male	11.5	29	135	150	85	93	7.4	168	4.1
18	Female	9	22	109	125	75	98	5.9	132	4.5
19	Male	9	25	118	120	80	62	4.1	160	6
20	Male	15	34	124	145	90	149	8.9	139	6.2

NO	ALP	Ca	P	GFR	pH	HCO3	Hb	cholesterol	total ptn	Albumin
1	417	8.9	4,9	13	7.34	22	9.2	115	6	3.2
2	479	9.1	2.7	9.8	7.28	19	11	109	8.1	4.6
3	321	8.6	6.5	8.5	7.45	22	7	176	7.2	3.1
4	718	6.8	3.4	13.5	7.37	21	7.7	156		3.4
5	661	6.5	5.6	12.1	7.25	19.6	7.4	184	7.4	3.2
6	455	8.9	4.3	9.5	7.27	22	11.5	208	6.8	4.1
7	376	8.7	5.8	8.5	7.32	19	8.8	121	8	4.1
8	1758	7.1	6.2	7.8	7.31	19.7	9.9	189	7.1	3.9
9	213	9.4	5.5	9.7	7.34	26	12.7	168	7.1	3.5
10	445	8.33	3,8	8.2	7.25	16	11	176	6.7	2.7

11	302	12.9	5.6	10	7.34	22	7.8	203	8.2	4.5
12	295	10.8	5.3	8.9	7.38	21	11.8	203	9.4	4.9
13	421	5.9	8.5	8.7	7.21	14	7.7	127	7.7	4
14	193	7.5	6.5	13	7.23	14	7.7	280	7.4	4.2
15	852	7.1	7.5	12	7.3	15.8	6.6	184	7.9	4.3
16	225	6.4	6	9.8	7.34	21	10.5	109	5.8	3.4
17	157	6.7	5.2	7.7	7.2	15.7	7	115		3.9
18	411	7.7	6	8.9	7.3	16	8.1	180	7.4	4.2
19	201	6.9	6	8.4	7.21	13	7	206	7.2	3.1
20	318	7.8	2.4	5.5	7.3	19	8.9	218	6.7	3.3
NO	Iron	TIBC	PTH	C/O			complication		DIAGNOSIS	
1	102	201	312	bone ache			osteomalacia		ESRD ON HD	
2	82	311	134						ESRD ON HD	
3	93	189	524	bone ache			deformity lower limbs		ESRD ON HD	
4	69	189	984	Fatiguability			deformity lower limbs		ESRD ON HD	
5	87	238	218						ESRD ON HD	
6	38	258	198	no complain					ESRD ON HD	
7	51	312	487	bone ache					ESRD ON HD	
8	61	361	1138	bone ache			pathological fracture+defomity		ESRD ON HD	
9	76	317	162	Fever					ESRD ON HD	
10	87	312	192.7	bone ache					ESRD ON HD	
11	63	214	131						ESRD ON HD	
12	97	295	144	no complain					ESRD ON HD	
13	97	273	284	boneache+tenderness			deformity lower limbs		ESRD ON HD	
14	54		167	bone ache					ESRD ON HD	
15	78	301	120	Fatiguability			stunted growth		ESRD ON HD	
16	118	167	182	bone ache			Rickets		ESRD ON HD	
17	45	201	163						ESRD ON HD	
18			956	boneache+tenderness			pathological# defor l.limbs		ESRD ON HD	
19			163	no complain					ESRD ON HD	
20	43	218	297	bone ache			pathological fracture+defomity		ESRD ON HD	
